trending Market Intelligence /marketintelligence/en/news-insights/trending/q9PzGEUX3vj6jXW6X08yjg2 content esgSubNav
In This List

Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Repros Therapeutics Inc. said its marketing application for enclomiphene in secondary hypogonadism is likely to receive a negative opinion in January 2018 from a European Medicines Agency committee.

The company received feedback regarding the forthcoming option, which will be issued by the Committee for Medicinal Products for Human Use, following an oral explanation.

The application was submitted by Renable Pharma Ltd., the company's U.K. unit.

Hypogonadism is a form of testosterone deficiency in adult males.

Allergan plc is in the process of acquiring Repros Therapeutics.